Modality
ASO
MOA
Anti-Aβ
Target
PD-1
Pathway
Epigenetic
RA
Development Pipeline
Preclinical
~Jul 2016
→ ~Oct 2017
Phase 1
~Jan 2018
→ ~Apr 2019
Phase 2
Jul 2019
→ Oct 2028
Phase 2Current
NCT08905329
1,228 pts·RA
2019-07→2026-09·Completed
NCT05294221
2,159 pts·RA
2023-12→2028-10·Completed
3,387 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-09-065mo awayPh2 Data· RA
2028-10-102.5y awayPh2 Data· RA
Trial Timeline
Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2
Complet…
P2
Complet…
Catalysts
Ph2 Data
2026-09-06 · 5mo away
RA
Ph2 Data
2028-10-10 · 2.5y away
RA
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08905329 | Phase 2 | RA | Completed | 1228 | LiverFat |
| NCT05294221 | Phase 2 | RA | Completed | 2159 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-7458 | Johnson & Johnson | Phase 1/2 | PD-1 | |
| LLY-8369 | Eli Lilly | Approved | Menin | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| Pexaosocimab | Daiichi Sankyo | Phase 2 | PD-1 | |
| MRN-8133 | Moderna | Phase 2 | PD-1 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| Semazasiran | BeiGene | Phase 1 | PD-1 | |
| Rimainavolisib | Illumina | Phase 2 | PD-1 | |
| Motanaritide | Intellia | Approved | PD-1 |